First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival. (PubMed, Leukemia) - Oct 3, 2026 - P3 | "Ibrutinib-venetoclax maintains superior OS, superior PFS, reduction in need for second-line treatment, and longer PFS duration without grade 3/4 TEAEs vs chlorambucil-obinutuzumab. Fixed-duration ibrutinib-venetoclax is an effective first-line treatment option for older/comorbid patients with previously untreated CLL, providing durable disease control and preserving future treatment options."
Adverse events • Journal • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • IGH
|
|
Ann Janssens; Arnon P Kater; Bennett Levitan; Carolyn Owen; Carsten U Niemann; Claire Kavanagh; George Follows; José-Ángel Hernández-Rivas; Kurt Baeten; Loic Ysebaert; Mark-David Levin; Martin Simkovic; Natasha Schuier; Nguyet Tran; Ohad Benjamini; Sergey Voloshin; Tadeusz Robak; Talha Munir; Vladimir Vorobyev
|